Zusammenfassung
In den letzten Jahren sind Medikamente entwickelt worden, die die Möglichkeiten der antidiabetischen Therapie erweitern und pathophysiologisch begründete Therapiekonzepte darstellen. Hier sind in erster Linie die DPP4-Hemmer und die Inkretinmimetika zu nennen, die die Wirkung der Inkretine beim Typ-2-Diabetiker restituieren. Auch mittels Rimonabant, das primär zur Gewichtsreduktion entwickelt wurde, ist eine signifikante Besserung der Parameter des Metabolischen Syndroms zu erreichen. Die dualen α/γ-PPAR-Agonisten zeigten in Studien erhebliche Nebenwirkungen. Glitazone verbessern signifikant die Insulinsensitivität, vermindern den Leberfettgehalt und erhöhen den Adiponektinspiegel. Auswertungen von Studien zeigen aber bisher nicht bekannte Nebenwirkungen. In den kommenden Jahren ist mit weiteren Medikamenten zur oralen Diabeteseinstellung zu rechnen, welche gezielt wichtige Enzyme des Stoffwechsels oder des Glukosetransports beeinflussen.
Abstract
In recent years new pharmacological agents have emerged, which enable us to widen the spectrum of diabetes management based on clear pathophysiological concepts. One should first of all mention the DPP4-inhibitors and the incretin mimetics, which have the potential of restoring the incretin effect in patients with type 2 diabetes mellitus. Moreover, it has been shown that the agent rimonabant, which was first used in order to achieve weight reduction, also contributed to the significant improvement of metabolic syndrome’s parameters. Recent studies have shown that the dual α/γ-PPAR-agonists have serious adverse effects. The thiazolidinediones (glitazones) significantly improve insulin sensitivity, diminish fat accumulation in the liver and increase circulating levels of adiponectin. Various adverse effects of glitazones have been described in recent studies. In the near future one should await the discovery of more oral antidiabetic agents acting through modulation of important enzymes in glucose metabolism and transport pathways.
Literatur
Ahren B (2003) Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 3: 365–372
Ahren B (2006) Vildagliptin: an inhibitor of dipeptidyl peotidase-4 with antidiabetic properties. Expert Opin Investig Drugs 15: 431–442
Aschner P, Kipnes M, Lunceford J et al.; Sitagliptin Study 021 Group (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 Diabetes. Diabetes Care 29: 2632–2637
Blüher M, Engeli S, Kloting M (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053–3060
DeFronzo RA, Ratner RE, Han J et al. (2005) Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with typ 2 diabetes. Diabetes Care 28: 1092–1100
Duttaroy A, Voelker F, Merriam K et al. (2005) The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases agoptosis. Diabetes (Suppl 1) 54: A14
Fari L, Bulotta A, Hirshberg B et al. (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149–5158
Gallwitz B (2007) DPP-4-Inhibitoren als neue Substanzklasse oraler Antidiabetika. Diabetes Stoffw Herz: 43–50
Home SJP, Beck-Nielsen H, Gomis R et al. RECORD Study Group (2007) Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 357: 28–38
Kendall DM, Riddle MC, Rosenstock J (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083–1091
Levy J, Atkinson AB, Bell PM et al. (1998) Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15: 290–296
Matthaei S, Häring HU (2007) Behandlung des Diabetes mellitus Typ 2. Praxisleitlinie der Deutschen Diabetes Gesellschaft. Diabetologie 2 (Suppl 2): S173–S177 http://www.deutsche-diabetes-gesellschaft.de
Mu J, Woods J, Zhou YP et al. (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55: 1695–1704
Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46–52
Nauck MA, Heimesaat MM, Behle K et al. (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87: 239–1246
Nauck MA, Meininger G, Sheng D et al.; Sitagliptin Study 024 Group (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomised, double-blind, non-inferiority trial. Diabetes Obes Metab: 1–12
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471
Nissen SE, Wolski K, Topol EJ (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294: 2581–2586
Rachman J, Barrow BA, Levy JC, Turner RC (1997) Near-normalisation of diurnal glucose concentrations by continuous administration of glucagons-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205–211
Rosenstock J, Brazg R, Andryuk P et al.; Sitagliptin Study 019 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor Sitagliptin added to ongoing Pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomised, double-blind, placebo-controlled, parallel-group study. Clin Ther 28: 1556–1568
Scheen AJ, Finer N, Hollander P et al.; RIO-Diabetes Study Group (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660–1672
Schwarz PE, Schuppenies A, Gruhl U et al. (2006) Prävention des Typ-2-Diabetes in Deutschland. Med Klin 101: 730–736
Toft-Nielsen MB, Damholt MB, Madsbad S et al. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86: 3717–3723
Interessenkonflikt
Keine Angaben.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fischer, S., Bornstein, S. Neue orale Antidiabetika. Internist 49, 495–501 (2008). https://doi.org/10.1007/s00108-007-1999-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-007-1999-2